
ABC 1183
CAS No. 1042735-18-1
ABC 1183 ( ABC1183 )
产品货号. M10214 CAS No. 1042735-18-1
ABC1183 是一种有效、选择性、口服活性的 GSK3α/β 和 CDK9 抑制剂,IC50 分别为 327/657 nM 和 321 nM (CDK9/cyclin T1)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥478 | 有现货 |
![]() ![]() |
10MG | ¥786 | 有现货 |
![]() ![]() |
25MG | ¥1604 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称ABC 1183
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述ABC1183 是一种有效、选择性、口服活性的 GSK3α/β 和 CDK9 抑制剂,IC50 分别为 327/657 nM 和 321 nM (CDK9/cyclin T1)。
-
产品描述ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modulates oncogenic signaling through changes in GSK3, GS and β-catenin phosphorylation and MCL1 expression; suppresses tumor growth and inflammation-driven gastrointestinal disease symptoms without organ or hematological toxicity in vivo.
-
体外实验ABC1183 (3 μM, 24 h) can block cell cycle progression and thus affect cell proliferation. Cell Cycle Analysis Cell Line:LNCaP human prostate cancer cells Concentration:3 μM Incubation Time:24 hours Result:Significantly reduced cells in the G1 and S phases and increased cells in the G2/M and sub-G1 cycle phases.
-
体内实验ABC1183 (oral gavage, 5 or 50 mg/kg) inhibits tumor proliferation through negative regulation of cell growth and pro-inflammatory signalling in male C57BL/6 mice. Animal Model:Male C57BL/6 mice with melanoma B16 Dosage:5 mg/kg Administration:Oral gavage; 5 times per week; 22 days Result:Reduced tumor size and no observed toxicity.Decreased the expression levels of GSK3 α /β, pSer21/9 and GS pSer641 but no change of total GS expression.Animal Model:Male C57BL/6 mice infected crohn’s disease Dosage:50 mg/kg Administration:Oral gavage; everyday; 3 days Result:Reduced TNF-α by 65%, IL-6 by 30% and IL-1β by 45%.Animal Model:Male C57BL/6 mice with ulcerative colitisDosage:50 mg/kg Administration:Oral gavage; once daily; 6 days Result:Increased the expression of the anti-inflammatory factor IL-10, while decreasing the pro-inflammatory factor IL-6.
-
同义词ABC1183
-
通路PI3K/Akt/mTOR signaling
-
靶点GSK-3
-
受体GSK-3
-
研究领域——
-
适应症——
化学信息
-
CAS Number1042735-18-1
-
分子量334.397
-
分子式C18H14N4OS
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 125 mg/mL (373.82 mM)
-
SMILESN#CC1=CC=C(C(C2=C(N)N=C(NC3=CC=C(C)C=C3)S2)=O)C=C1
-
化学全称4-(4-Amino-2-p-tolylamino-thiazole-5-carbonyl)-benzonitrile
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Schrecengost RS, et al. J Pharmacol Exp Ther. 2018 Feb 6. pii: jpet.117.245738.
产品手册




关联产品
-
GSK3β inhibitor II
GSK3β inhibitor II 是 GSK3β 的抑制剂。GSK3β inhibitor II 可用于阿尔茨海默病 (AD) 的研究。
-
5-Bromoindole
5-溴吲哚是一种潜在的糖原合酶激酶3(GSK-3)抑制剂,也是一种重要的医药化工中间体。
-
CCG 203769
CCG 203769 是 RGS4 的选择性抑制剂,对于 RGS4-Gαo 蛋白质-蛋白质相互作用的 IC50 为 17 nM。